several programmable transcription factors exist based on the versatile Cas9 protein, yet their relative potency and effectiveness across various cell types and species remain unexplored. here, we compare Cas9 activator systems and examine their ability to induce robust gene expression in several human, mouse, and fly cell lines. We also explore the potential for improved activation through the combination of the most potent activator systems, and we assess the role of cooperativity in maximizing gene expression.
multiple loci can be upregulated, requiring only the provision of an extra single guide RNA (sgRNA) for each additional locus one desires to activate. Previous work has shown a general decrease in gene activation upon multiplexing, but whether this is true of all systems is unknown 12, 19 . To address this question, we performed a series of multiplex activation experiments (Supplementary Fig. 3) . When activating three genes at once with VPR, SAM, or Suntag, no system appeared superior to the others, and all systems showed levels of activation within an order of magnitude of each other for the majority of target genes. This is a somewhat surprising finding given that SAM and Suntag are believed to require the assembly of large, multimember protein complexes in order to generate a highly competent activator. To further investigate the limitations of multiplexing, we simultaneously directed each of the systems to six target genes at once. Even within this more complex activation scheme, all systems showed similar levels of relative gene activation, a fact that highlighted the robustness of these systems as tools to actuate complex transcriptional regulation ( Fig. 2b) . Of note, we observed within our control samples inherent variation in the level of basal gene expression, upon which we based our calculation of relative fold induction. Therefore, by comparing expression data across experiments, we were unable to make comparisons with regard to the absolute amount of activation a given system can perform when targeted to a single gene versus multiple genes.
An important concern for any Cas9-based technology is the specificity of the desired effect. It has been demonstrated that Cas9 binds promiscuously throughout the genome 23 . This effect could potentially result in aberrant transcription for Cas9 activators if they were to bind to the wrong promoter. To test the specificity of each activator, we performed whole RNA-seq on samples, with each of our activators targeting HBG1 (Fig. 3) . We found that the correlation in gene expression between each activator and our control sample was very similar to the correlation between biological replicates in our data set (R ~ 0.98 in each case), indicating that gene expression is not broadly affected by the presence of any activator ( Fig. 3a) . Disregarding noise from genes with low baseline expression (<0.1 TPM, transcripts per million), HBG1 was the most highly upregulated gene in each sample except for VP64, indicating that the activators are highly specific (Fig. 3b) .
To further explore the generality of the trends we observed within HEK293T cells, we targeted a smaller subset of genes within other biomedically relevant human cell lines (HeLa, U-2 OS, and MCF7). While SAM demonstrated more potent activation in HeLa cells, Suntag and VPR were the more potent activators in U-2 OS and MCF7 cells ( Fig. 4a and Supplementary  Fig. 4a ). The biological basis for these cell-line-specific differences remains to be determined, but they are not likely to be due to differences in basal expression state given that HBG1 and TTN are expressed at a similarly low basal state across the tested cell lines (data not shown).
Because human cell lines represent only a single context in which dCas9-based activators might be employed, we performed a series of experiments within mouse N2A and 3T3 cells as well as in Drosophila S2R+ cells 13 npg ( Supplementary Fig. 7 ). Toward this end, a hybrid SAM+Scaffold sgRNA was generated along with a series of chimeras containing combinations of select portions of each system. Despite our exhaustive attempts, there was no combination of dCas9 activators, secondary effector component alteration, or sgRNA modification that could lead to a chimeric system with enhanced transcriptional regulatory capacity for either single or multiplex gene induction.
Previous work with the first-generation dCas9-VP64 activator uncovered a role for cooperativity in enabling synergistic increases in gene activation 7, 10, 11, 24, 25 . Whether this observation is also true for the significantly more potent second-generation activators remains unexplored. It is likely that the extendibility of these newer systems may be limited from further increasing gene expression on account of insufficient host resources (such as local RNA polymerase concentrations near a given locus) 26 . To study the effects of recruiting multiple dCas9 activator complexes to the same locus, we generated three sgRNAs against weakly, intermediately, and highly expressed gene targets (ASCL1, NEUROD1, and CXCR4, respectively) within HEK293T cells and then transfected each of the sgRNAs alone or all the sgRNAs against a given target gene at once. Simultaneous targeting of the same gene with multiple sgRNAs led to additive or greater levels of gene activation ( Fig. 4c ). activators showed improved activity as compared to that of the dCas9-VP64 standard. Within mouse and Drosophila cells, VPR, SAM, and Suntag showed similar levels of gene induction (within five-fold of each other), and which of these activators demonstrated the most potency varied depending on the target analyzed ( Fig. 4b and Supplementary Fig. 4b) .
Given that VPR, SAM, and Suntag represent divergent approaches to Cas9 activator design, we sought to determine if any of the activator components could be combined to generate a hybrid activator with increased potency. First, we naively combined each of the systems (Supplementary Fig. 5 ). For example, we used the Suntag dCas9 component and the SAM-modified sgRNA to simultaneously recruit both scFv-VP64 to the end of dCas9 and p65-hsf1 to the sgRNA. In addition, we conducted tests in order to determine whether systems such as SAM or Suntag that rely on recruiting several copies of their activator (p65-hsf1 or VP64, respectively) might be enhanced by nucleating a different activator such as VPR ( Supplementary Fig. 6 ). Finally, we investigated whether the MS2 hairpins used within the SAM system to recruit the MS2 binding protein p65-hsf1 activator component might be enhanced by combining these hairpins either in part or in their entirety with the scaffold method of MS2-binding-protein-mediated activator recruitment npg delivery, familiarity with the system, and access to the necessary reagents, may be more practical concerns 27 .
It is reassuring that the second-generation activators show robust activation even when employed in organisms, such as Drosophila, that are very distantly related to the human cell lines in which these tools were developed. The demonstrated portability of these dCas9 activators across disparate model systems and species suggests that they hold potential as universal genetic tools. It is likely that these systems will prove effective across a wide range of scientifically interesting organisms with minimal additional engineering.
Our attempts to build an improved chimeric activator by fusing elements from VPR, SAM, and Suntag were unsuccessful (Supplementary Figs. 5-7) . This is particularly unexpected given the drastically different ways in which these systems generate functional activators [12] [13] [14] [15] [16] . It is difficult to disentangle issues such as steric interference between neighboring activator elements from the possibility that each of these systems 28 , while different, may be interacting with a similar subset of the transcriptional regulatory machinery 29, 30 . Future efforts to improve dCas9-based activators may benefit from exploring other unique architectures or novel activation domains, along with examining the use of epigenetic modifiers to provide complementary mechanisms to further enhance activation 18, 31 .
While we did not perform experiments to explicitly address potential differences in sgRNA binding site preferences between VPR, SAM, and Suntag, it is telling that for experiments in which the activity of several sgRNAs was examined against the same gene, the activators showed the same sgRNAs to be either the most potent or the least potent (Fig. 4c) . These data suggest that the rules governing activator placement within a given promoter region are shared. It will be interesting to characterize the properties shared by highly potent sgRNAs to help distinguish effects of distance from the transcriptional start site from features such as sgRNA sequence composition and stability 12,15,23,32,33 . In addition, disCussion Cas9-based activation represents a powerful method to study gain-of-function phenomena on genomic scales and has already been used to uncover mechanisms of toxin-mediated cell death and tumor cell resistance to targeted therapy 12, 15 . While it is tempting for those analyzing the initial Cas9 activator publications to make cross-study comparisons, these types of analyses are fraught with confounding variables, such as differences in the cell line used, sgRNA selected, amount of Cas9 complex transfected, and time until RNA extraction. In addition, variation that is often overlooked in the basal expression level of some of the more weakly expressed target genes can lead to large differences in the perceived performance of one system over another. Within our own data, there are instances where the absolute level of target gene activation differs because of confounding variables and variation in basal expression levels, despite the fact that each of our experiments was performed under similar conditions ( Fig. 1  and Supplementary Fig. 1 ). These differences in activation levels between experiments emphasize the need for comparisons across activators to be performed within a single experiment if users want to make statements with regard to absolute levels of gene induction. In contrast, for cases where understanding a relative difference in performance is the primary goal, differences in basal expression state will no longer play a role, as each activator is compared to the other activators, eliminating variance due to basal expression state.
Our results demonstrate that, across a range of target genes and cellular environments, the VPR, SAM, and Suntag systems are consistently superior to the previous VP64 standard. In addition, while SAM exhibits more potent activation in some contexts, VPR, SAM, and Suntag generally fall within an order of magnitude of each other with regard to fold increase in gene expression. It is additionally comforting that each activator was similarly specific to a given target. This suggests that constraints other than the ability to induce gene expression or specificity, such as ease of the fact that we are able to achieve increased levels of programmable gene induction by employing multiple sgRNAs against a single target gene suggests that none of the current Cas9 activators have yet achieved 'maximal activation' since, if they had, each activator would not have been aided by the use of multiple guides. These results suggest that continued improvements to Cas9 activators are still possible and should aid in generating a more reliable tool for performing systematic genome-wide screens.
Although it was not highlighted in any of the original studies for VPR, SAM, or Suntag, our results suggest that the combination of multiple sgRNAs represents a viable strategy to enhance gene expression in cases where maximal induction is desired. This strategy may be most valuable for highly expressed genes, which are generally recalcitrant to large amounts of overexpression from the native locus 12, 13 . It could also be used to ensure that all genes are consistently upregulated given that even for easily upregulated genes there can be over a hundred-fold difference in potency between various sgRNAs (Fig. 4c) .
methods
Methods and any associated references are available in the online version of the paper.
Accession codes. Gene Expression Omnibus: GSE80611.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. online methods Vector design and construction. Vectors used and guide scaffolds will be deposited to Addgene. dCas9-VP64 (Addgene #47319), dCas9-VPR (Addgene #63798), dCas9-VP64 (for SAM activation Addgene #61425), MCP-p65-hsf1 (Addgene #61426), dCas9-10xGCN4 (Addgene #60903), scFv-VP64 (Addgene #60904), dCas9-p300core (Addgene #61357), dCas9-VP160 (Addgene #48225), Cas9-m4 (Addgene #47316), and MCP-VP64 7 were previously described.
For all systems tested the original vectors deposited to Addgene were employed, allowing us to use the presumably optimal expression vector decided upon by the various depositing laboratories. dCas9-VP64, dCas9-VPR, dCas9-p300, dCas9-VP160, and dCas9-m4 constructs were all driven under CMV promoters. dCas9-VP64 (for SAM activation) and MCP-p65-hsf1 used EF1alpha promoters and dCas9-10xGCN4 and scFv-VP64 used SV40 promoters.
Gibson cloning was used to make all variants. For SAM and Scaffold sgRNA variants, gene blocks were used (Integrated DNA Technologies). See Supplementary Note 2 for full sequence information.
All dCas9 activator components were cloned into a Drosophila pActin vector using Gibson assembly 34, 35 , adding a Kozak sequence (GCCACC) immediately upstream of the start codon.
To generate Drosophila MS2-containing sgRNA expression vectors for SAM and Scaffold, the pCFD3 plasmid was modified via Gibson assembly to include the indicated sgRNA tails 36 . For all sgRNA plasmids guide oligos were cloned using a BbsI digest 36 .
Mammalian cell culture. All human and mouse cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS and penicillin-streptomycin (all from ThermoFisher Scientific) in an incubator set at 5% CO 2 and 37 °C. MCF7 (gift of J. Lee, Cold Spring Harbor, Cold Spring Harbor, New York) media was supplemented with 0.01 mg/ml human recombinant insulin (EMD Millipore). HEK293Ts, HeLas (both gifts of P. Mali, UCSD, San Diego, CA), U-2 OS (ATCC HTB-96), MCF7s, N2As (ATCC CCL-131), and NIH-3T3s (gift of S. Shipman, Harvard Medical School, Boston, Massachusetts) were seeded into 24-well plates for transfection.
Cell lines were not tested for authenticity and were tested yearly for mycoplasma.
Mammalian transfections. DNA was aliquoted into individual tubes before transfection. 25 ng of plasmid DNA containing the Cas9 component and 10 ng of plasmid DNA with the guide were transfected into each well. For activators requiring a second component (Suntag, SAM, and Scaffold), 100 ng of plasmid DNA containing that component was also transfected. For all the other activators, 100 ng of an empty vector (Puc19) was substituted for the secondary component in order to ensure equal amounts of DNA were transfected. For experiments involving multiple guides targeted toward one gene, the amount of sgRNA plasmid per transfection was scaled so that the total plasmid sgRNA in each well was 10 ng. For example, for three sgRNAs activating one gene, 3.33 ng of each guide was transfected. In experiments involving multiple guides targeted toward different genes, 10 ng of sgRNA plasmid DNA was transfected per target. For all sgRNA spacer sequences, please see Supplementary Table 1 .
293T cells were transfected with Lipofectamine 2000 (ThermoFisher Scientific) using the following protocol. For each transfection, a stock solution of 50 µl of Opti-Mem (ThermoFisher Scientific) and 2 µl of Lipofectamine 2000 (ThermoFisher Scientific) per transfection was made. The solution was then vortexed and incubated for five minutes. The Optimem-Lipofectamine solution was then added to the individual aliquots of DNA, vortexed, and spun in a centrifuge at 100 rpm for 1 min. The DNA was then incubated for 30 min before being added to the cells.
All other cell lines were transfected with Lipofectamine 3000 (ThermoFisher Scientific) using the following protocol. 25 µl of Opti-MEM was added to each DNA aliquot along with 1 µl P3000 reagent per transfection. Master mixes of Opti-MEM and Lipofectamine 3000 were prepared with 25 µl of Opti-Mem and 1 µl or 0.5 µl of Lipofectamine 3000 per transfection. MCF7s, N2As, and U-2 OSes were transfected using 1 µl of P3000 reagent and 0.5 µl of Lipofectamine 3000 reagent per transfection. N2As and NIH-3T3s were transfected with 1 µl of P3000 reagent and 1 µl of Lipofectamine 3000 reagent per transfection. The solutions were vortexed and incubated separately for 5 min before 25 µl of the Lipofectamine 3000-Opti-Mem mix per transfection was added to the DNA aliquots. These new solutions were then vortexed, centrifuged at 100 rpm for 1 min, incubated for 30 min, and then added to the cells.
To avoid excess toxicity to the cells, media was changed after 24 h for the 293T, N2A, and NIH-3T3 cells. Otherwise, media was changed after 4 h.
RNA extraction and qPCR analysis for mammalian cell lines.
Cells were harvested for RNA 48 h post-transfection. RNA was extracted using the RNeasy Plus Mini Kit (Qiagen). cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad) using 500 ng of RNA per cDNA reaction. qPCR reactions were prepared using the KAPA SYBR Fast Universal 2× quantitative PCR kit using 0.5 µl of cDNA per reaction in a 20 µl total reaction volume. Gene expression was normalized to the expression of the gene ACTB for human cell lines and the mouse ortholog (Actb) for mouse cell lines as an internal housekeeping gene. Cycling conditions were as follows: 95° for 1 min, 95° for 10 s, and 60° for 30 s. The latter two steps cycled for 50 repeats with plate reads taken after the 60° step. If a sample failed to amplify after 50 cycles, an arbitrary Cq count of 50 was substituted (this occurred in a single instance). For qPCR primer sequences, please see Supplementary Table 2. RNA-seq analysis. For each sample, 100 ng of total RNA was DNase treated with Turbo DNase (ThermoFisher Scientific) at 37 °C for 30 min and then cleaned up with Agenocourt RNAClean XP Beads (Beckman Coulter). The RNA samples were polyA selected using Dynabeads mRNA Direct Purification Kit (ThermoFisher Scientific). RNA-Seq libraries were constructed using Maxima H Minus First Strand Synthesis Kit (ThermoFisher Scientific) with random hexamers and then the NEBNext mRNA Second Strand Synthesis Module (New England BioLabs). The resulting cDNA was cleaned up with Agencourt AMPure XP Beads (Beckman Coulter) and then went into the Nextera XT DNA Library Prep Kit (Illumina). Final libraries were once again cleaned with Agencourt AMPure XP Beads and analyzed on a BioAnalyzer using a High Sensitivity DNA Analysis Kit (Agilent). 
